Among 25 transfusion-dependent patients with myelodysplastic syndromes (MDS) receiving up to 300 mg/d thalidomide p.o., 5 became transfusion-free within 4-9 weeks and for 6 to +24 months. Responders had a recent diagnosis, normal karyotype, no excess of marrow blasts and were younger than non-responders. Thalidomide may be effective for treating anemia in selected MDS patients.
|Number of pages||3|
|Publication status||Published - 2002|
- Fetal hemoglobin
- Myelodysplastic syndromes
ASJC Scopus subject areas